Clinical Trial Details
— Status: Active, not recruiting
Administrative data
| NCT number |
NCT00667030 |
| Other study ID # |
HP-00041199 |
| Secondary ID |
|
| Status |
Active, not recruiting |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
July 2005 |
| Est. completion date |
December 2025 |
Study information
| Verified date |
November 2023 |
| Source |
University of Maryland, Baltimore |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Over half of adults in this country are overweight. This increases risk for heart and blood
pressure problems, cancer, stroke and arthritis. While it is difficult to lose large amounts
of weight and keep it off, even small amounts of weight loss can improve health. Furthermore,
fat is increasingly recognized as a source of substances that increase inflammation. It may
be that some of the adverse consequences of being overweight are due to increased
inflammation. We are asking you to volunteer for a research study in which you may lose a
moderate amount of weight and increase your activity. It is important that you read and
understand the information on this form.
The purposes of these studies are to determine the influence(s) of age and body composition
on the production of inflammatory chemicals by fat (adipose tissue), the mechanisms
controlling this, and if a weight loss and aerobic exercise intervention results in a
decrease in inflammation.
Description:
Adipose tissue is increasingly recognized as more than an inert depot serving not only to
accept and store excess energy in the form of triglycerides, but also to secrete hormones and
adipokines that have substantial effects on lipid and glucose metabolism. Furthermore, there
are depot differences in metabolic function, as well as adipokine content. However, the
physiology both underlying and consequential to these observations remains unknown. This
research is therefore designed to examine:
1) the effects of aging and obesity on regional adipokine secretion and expression, 2)
whether elevated adipokine levels in older obese people are due to increased macrophage
infiltration into subcutaneous adipose tissue and/or related to total, subcutaneous or
visceral abdominal fat (SAT or VAT) distribution, and 3) the relationship of adipokines to
insulin resistance and the constituents of the metabolic syndrome.
Specifically, we aim to determine:
1. if the expression and secretion of a) the inflammatory markers SAA, IL-6, TNF-a, MCP-1
is greater, and b) the anti-inflammatory hormone adiponectin is lower in SC abdominal
and gluteal adipose tissue from older, compared to middle-aged and younger obese
subjects across a narrow range of obesity and waist circumference;
2. if these age-associated changes in adipokine production are a)due to the degree of
macrophage infiltration of regional adipose tissue, and/or differences in a greater
degree of visceral and/or differences in ABD fat distribution (SAT, VAT), and b) related
to glucose and lipid metabolic profiles of the subjects; and
3. the effects of a WL+AEX intervention on regional adipokine expression and secretion,
circulating levels of CRP and the above adipokines, and glucose and lipid metabolism in
a subset of obese sedentary individuals with greater than two components of the
metabolic syndrome.
